Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997;123(4):195-200.
doi: 10.1007/BF01240315.

In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance

H Arioka  1 , K Nishio, Y Heike, S Abe, N Saijo
Affiliations

In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance

H Arioka et al. J Cancer Res Clin Oncol. 1997.

Abstract

Rhizoxin is an antineoplastic drug that inhibits tubulin polymerization. In this study, we demonstrated that rhizoxin was approximately twice as active in vitro against a human small-cell lung cancer cell line with non-P-glycoprotein-mediated resistance to vindesine, H69/VDS, as against its parental line, H69. Tubulin polymerization in H69/VDS, demonstrated by Western blot analysis, was inhibited markedly by rhizoxin compared with that in H69, in a concentration-dependent manner. A drug-accumulation study showed that the intracellular rhizoxin level in H69/VDS was 15% lower than that in H69, whereas efflux from H69/VDS was enhanced slightly. These results indicate that enhanced inhibition of tubulin polymerization rather than increased intracellular drug concentration accounted for the higher sensitivity of H69/VDS to rhizoxin. In an experiment using mice with severe combined immunodeficiency and inoculated subcutaneously with H69/VDS, in vivo tumor growth was reduced markedly by three intermittent intraperitoneal doses of rhizoxin compared with that in mice inoculated with H69. Three weeks after the last rhizoxin dose, the relative treated/untreated tumor volumes were 0.29 for H69, but only 0.06 for H69/VDS, indicating that H69/VDS regrowth was minimal even after a 3-week treatment-free period. In conclusion, rhizoxin conquers vindesine resistance of a human small-cell lung cancer cell line in vitro and in vivo.

PubMed Disclaimer

References

    1. Bai RL, Pettit GR, Hamel E (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotude and vinca alkaloid sites. J Biol Chem 265:17141–17149 - PubMed
    1. Bissett D, Graham MA, Setanoians A, Chadwick GA, Wilson P, Koier I, Henrar R, Schwartsmann G, Cassidy J, Kaye SB, Kerr DJ (1992) Phase I and pharmacokinetic study of rhizoxin. Cancer Res 52:2894–2898 - PubMed
    1. Cabral F, Barlow SB (1989) Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 3:1593–1599 - PubMed
    1. Cabral F, Sobel ME, Gottesman MM (1980) CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin. Cell 20:29–36 - PubMed
    1. Cole SPC (1996) Multidrug resistance in human lung cancer and topoisomerase II. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT (eds) Lung cancer: principles and practice. Lippincott-Raven, Philadelphia, pp 169–204

Publication types

LinkOut - more resources